title: Targeting of single-chain urokinase plasminogen activator by conjugation to an antiplatelet antibody results in enhanced clot lysis.
authors.affiliation: Medizinische Klinik III (Kardiologie), Universität Heidelberg, Germany.
authors.forename: C
authors.initials: C
authors.lastname: Bode
authors.forename: T
authors.initials: T
authors.lastname: Nordt
authors.forename: U
authors.initials: U
authors.lastname: Detlefs-Bartels
authors.forename: M S
authors.initials: MS
authors.lastname: Runge
authors.forename: M
authors.initials: M
authors.lastname: Arens
authors.forename: W
authors.initials: W
authors.lastname: Kübler
authors.forename: E
authors.initials: E
authors.lastname: Haber
mesh_terms: D000906:Antibodies / Q000008:administration & dosage*; D001792:Blood Platelets / Q000187:drug effects / Q000276:immunology*; D005341:Fibrinolysin / Q000378:metabolism; D006801:Humans; D066298:In Vitro Techniques; D015912:Thrombolytic Therapy / Q000379:methods; D013927:Thrombosis / Q000188:drug therapy; D014568:Urokinase-Type Plasminogen Activator / Q000008:administration & dosage*
chemical_list: D000906:Antibodies; D005341:Fibrinolysin; D014568:Urokinase-Type Plasminogen Activator